Carbetocin - Ferring Pharmaceuticals
Alternative Names: Carbetocin Ferring; CARITEC; Duratobal; Duratocin; Lonactene; PabalLatest Information Update: 06 Oct 2023
At a glance
- Originator Ferring Pharmaceuticals
- Developer Ferring Pharmaceuticals; Merck & Co; Sun Pharmaceutical Industries; World Health Organization
- Class Antihaemorrhagics; Oxytocics; Posterior pituitary hormones
- Mechanism of Action Oxytocin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Postpartum haemorrhage; Uterine inertia
Most Recent Events
- 21 Sep 2023 Ferring Pharmaceuticals completes a phase I trial in Postpartum haemorrhage (In volunteers) in USA (IV) (NCT05924321)
- 25 May 2023 Phase-I clinical trials in Postpartum haemorrhage (In adults, In volunteers) in USA (IV, Infusion) (NCT05924321)
- 28 Apr 2023 Phase-III clinical trials in Postpartum haemorrhage in USA (IV) prior to April 2023 (Ferring Pharmaceuticals pipeline, April 2023)